Dendritic cell vaccine head and neck cancer - SOTIOAlternative Names: DCVAC/HNCa
Latest Information Update: 05 Jun 2014
At a glance
- Originator SOTIO
- Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Head and neck cancer
Most Recent Events
- 01 Jan 2014 Clinical trials in Head and neck cancer in European Union (SC)